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Development of a Bayesian
response-adaptive trial design
for the Dexamethasone for
Excessive Menstruation study
Christian Holm Hansen,1 Pamela Warner,2 Richard A Parker,3,4
Brian R Walker,5 Hilary OD Critchley6 and Christopher J Weir2,4
Abstract
It is often unclear what specific adaptive trial design features lead to an efficient design which is also feasible to
implement. This article describes the preparatory simulation study for a Bayesian response-adaptive dose-finding trial
design. Dexamethasone for Excessive Menstruation aims to assess the efficacy of Dexamethasone in reducing excessive
menstrual bleeding and to determine the best dose for further study. To maximise learning about the dose response,
patients receive placebo or an active dose with randomisation probabilities adapting based on evidence from patients
already recruited. The dose-response relationship is estimated using a flexible Bayesian Normal Dynamic Linear Model.
Several competing design options were considered including: number of doses, proportion assigned to placebo,
adaptation criterion, and number and timing of adaptations. We performed a fractional factorial study using SAS
software to simulate virtual trial data for candidate adaptive designs under a variety of scenarios and to invoke
WinBUGS for Bayesian model estimation. We analysed the simulated trial results using Normal linear models to
estimate the effects of each design feature on empirical type I error and statistical power. Our readily-implemented
approach using widely available statistical software identified a final design which performed robustly across a range of
potential trial scenarios.
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1 Introduction
Adaptive designs generally oﬀer added ﬂexibility and eﬃciency over conventional trial designs. However, it is
diﬃcult to select the design options that provide an eﬀective adaptive design which is also feasible to implement.
Before deciding on a particular design, it is generally advisable to carry out a simulation study.
The methodology of Bayesian adaptive designs has grown steadily in recent years; alongside this, publications
providing guidance on simulation studies for the development of Bayesian response-adaptive designs1 are a
valuable resource. Characterising the properties of competing adaptive designs and choosing a ‘best design’ to
take forward is not a trivial task. In this paper, we describe our experiences from a simulation study which was
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conducted to develop the response-adaptive dose-ﬁnding study design for the MRC-funded Dexamethasone for
Excessive Menstruation trial (DexFEM; MRC reference: MR/J003611/1).
2 Outline
A brief account of the background and motivation for the DexFEM study is provided in section 3 along with a
description of the methods planned for the analysis of this adaptive trial. The design development study is
introduced in section 4 which gives an account of the design options and scenarios that are investigated in the
trial simulations. Sections 5 and 6 give details of the simulation engine and the methods used to summarise the
simulated trial results. The ﬁndings from the design development study are presented in section 7. Section 8
explains the subsequent choice of the adaptive design for DexFEM followed by more general discussion of our
approach in a wider context in section 9.
3 The DexFEM study
Heavy Menstrual Bleeding (HMB) is a common problem, yet existing medical treatments are often ineﬀective.
Surgical treatments such as hysterectomy, are unacceptable to many, particularly those who wish to preserve their
fertility. DexFEM aims to establish if Dexamethasone (a synthetic glucocorticoid) taken orally is eﬀective in
reducing menstrual blood loss (MBL) in women with heavy menstrual bleeding.
Women with HMB may have glucocorticoid deﬁciency in the lining of the womb (endometrium) and as a
consequence impaired blood vessel function and increased menstrual blood loss.2 We propose ‘‘rescue’’ of such a
deﬁciency could reduce excessive menstrual bleeding. The published DexFEM protocol provides further details of
the trial.3
The optimal dose for achieving eﬃcacy and few adverse eﬀects is unknown but is likely to be between 0.4mg
and 1.8mg per day. The aims of the DexFEM trial are: (1) to establish whether Dexamethasone in this dose range
is eﬃcacious in reducing menstrual blood loss and (2) to identify which is the best dose for further study in a later
trial.
To estimate the dose-response curve we aim to enrol up to 108 women with HMB to achieve 100 completers in a
response-adaptive, multi-arm, parallel-group dose-ﬁnding trial. Participants are randomised to receive either
placebo or one of several active doses in the range 0.4mg to 1.8mg. Allocation probabilities are equal across
the active doses at the start of recruitment but will be updated for subsequent trial participants as outcome data
begin to accrue and information is gathered about the likely shape of the dose-response curve. This strategy has
the advantage that more information is obtained in the critical region of the underlying dose-response curve and
fewer women are randomised to less eﬀective doses. To limit potential bias in the randomised comparisons at the
end of the study due to a drift in participant characteristics across time, the placebo allocation rate will remain
constant throughout the study. Thus, the allocation rate to placebo is the only one that is not subject to
adaptation.
Two characteristics of menstrual bleeding research are relevant to DexFEM. (1) Cycle. The symptoms of
HMB occur only cyclically according to the pattern of menstruation (most usually 5 to 8 days menstruation
starting every 26 to 29 days, but variable even within women). In DexFEM, we wish to trial three cycles of
treatment. (2) Outcome. Following collection of sanitary protection by the patient, laboratory estimation of
menstrual blood loss volume for the period can be achieved within a few days of the end of the period making it
a suitable outcome for use in an adaptive design. In DexFEM only the second and third treated cycles involve
menstrual blood volume measurement.
3.1 Modelling the dose-response
The dose-response curve is estimated using Bayesian methods in a second order Normal Dynamic Linear Model4
(NDLM). Such models oﬀer ﬂexibility over non-dynamic models as few restrictions are placed on the shape of the
estimated curve. NDLMs also lead to eﬃciency gains since the treatment eﬀect estimate at a given dose is also
informed by that of neighbouring doses.
The NDLM is speciﬁed in terms of an observation equation and an evolution equation. Our observation
equation
Yi ¼ j þ Ybli þ i i ¼ 1, . . . , 100; j ¼ 1, . . . , J; i  i:i:d: Nð0, 2 Þ
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models Yi, the MBL change from baseline to follow-up in subject i, as a linear function of the mean-centred
baseline MBL Ybli, and j, the treatment eﬀect at dose level j.  is the regression coeﬃcient for Ybli and i is the
observational error term.
The evolution equation
j ¼ j1 þ j1 þ !j
j ¼ j1 þ "j j ¼ 1, . . . , J;!j, "j  i:i:d: Nð0, 2!Þ
equates the treatment eﬀect at dose level j to the treatment eﬀect at the previous dose level plus a systematic
deviation, j 1, and an evolution error, !j. Finally j, the change in treatment eﬀect from dose level j to dose
level jþ 1, is essentially modelled as a random walk with step size governed by N(j 1, !2). The model
formulation therefore assumes linear changes in the treatment eﬀect from one dose level to the next but
avoids restricting the overall curve to follow a particular parametric speciﬁcation or even monotonicity
(Figure 1). i, !j and "j are mutually as well as internally independent. !j and "j are restricted to have the
same variance to limit the number of parameters needing estimated with this relatively small sample size.
Similarly, the observation and evolution error variances are assumed constant for all subjects and dose levels.
We used the freely available WinBUGS software5 to estimate this system of equations using Bayesian methods.
We deﬁned the variance of the evolution error as a multiple of the observational error variance such that
!
2¼W2. A uniform U(0.001, 100) prior distribution was speciﬁed for W and a vague half-normal prior
distribution N(0, 100), deﬁned only on the non-negative range of the scale, was placed on 
2. We also
speciﬁed prior N(0, 10000) distributions for 0, 0, and .
3.2 Adaptation after interim analyses
A conventional design might randomise all trial participants evenly across the active dose range before deriving,
at the end, a ﬁnal model estimate of the dose-response curve. With our adaptive design we will, while
recruitment is still ongoing, apply the NDLM to the available outcome data already accrued to obtain
Figure 1. Illustration of a Normal Dynamic Linear Model fit to simulated trial data based on a theoretical dose–response
relationship. The figure shows the theoretical dose-response curve, the piecewise linear fit derived from the Normal Dynamic Linear
Model and the actual observed means from a single simulated trial realisation (stars).The outlying mean at 0.4mg was based on just six
patients randomised to this dose and consequently had a relatively smaller influence on the model estimate of the treatment effect at
that dose.
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intermediate estimates of the dose-response curve. Evidence of emerging trends can then inform adaptation of
randomisation probabilities to the active doses for future trial participants in a way that optimises estimation of
the dose-response curve according to some pre-deﬁned criterion. Typically as the trial progresses, more
participants are randomised to doses which are emerging as more eﬀective so that the dose-response curve in
the range containing these doses may be estimated with greater precision than would have been the case in a
conventional design.
The criterion on which adaptation is based might be a simple rule, for example to allocate future participants
using probabilities that are proportional to current eﬀect estimates at each dose level. It might also be a more
complex function of the predicted utility of future randomisations at each dose level, for example using a measure
of the precision with which the optimal dose level is estimated, or alternatively, a measure of the precision with
which eﬃcacy is estimated at the optimal dose level. The criterion should reﬂect the trial objectives and is likely to
diﬀer depending on whether the primary interest is to obtain a robust estimate of the dose-response curve across
the entire dose range or just around the optimum dose level. As our second aim is to identify the best dose for
further study, we applied a commonly used deﬁnition of the optimal dose: the ED95, the smallest dose which
achieves at least 95% of the maximum treatment eﬀect.
4 The design development study
We aimed to develop a feasible adaptive design: that is, one with a limited number of scheduled adaptations and a
speciﬁed number of possible doses (to allow the pharmacy to prepare capsules in advance). A balance was
therefore needed between satisfying these feasibility criteria and obtaining eﬀective adaptation. To this end, we
considered several diﬀerent designs and assessed the suitability of each for DexFEM in a comprehensive pre-trial
simulation study. The aim of the design development study was to generate simulated trial results to characterise
the properties of candidate designs in terms of type I error and statistical power and ultimately to identify one
design which would perform well across a broad range of scenarios.
4.1 Design options
4.1.1 Dose levels
A daily Dexamethasone dose of 1.5mg was used in two small pilot trials, the dose being selected based on
experience with the drug in other indications and its planned use for 5-day treatment across repeated menstrual
cycles. No safety concerns emerged. The adaptive trial provides an opportunity to estimate the dose-response
curve over as wide a dose range as possible. Clinical judgment was that 1.8mg was the maximum dose that should
be tested, so the daily dose levels selected for study were 0.4mg, 0.8mg, 1.0mg, 1.2mg, 1.5mg and 1.8mg.
It was not clear how many doses we could reliably study in the trial. Would a design with the maximum
practical number of doses perform better since intervals between observed points on the dose-response curve are
shorter, or would a design with fewer doses perform better since better precision would be achieved in the
treatment eﬀect estimates at each dose level? We investigated this in the design development study (Table 1).
4.1.2 Number and spacing of adaptations
In principle, the ideal design would encompass model re-estimation and subsequent adaptation of future
allocation probabilities to each of the active doses with every new MBL measurement collected. In practice,
a fully sequential design of this sort would be unnecessarily challenging and work-intensive and with little
eﬃciency gain over a simpler design with fewer adaptations (based on what we learned from initial
exploratory simulation work). We assessed the performance of designs with one, three and ﬁve adaptations
over the course of recruitment as well as non-adaptive designs (zero adaptations) for comparison. Within each
design, adaptations were scheduled at pre-deﬁned points during the recruitment phase. An example of a design
with one adaptation [see Table 1, section 1.2(b)] is a trial where the ﬁrst 50 participants are allocated with equal
probability to any of the dose levels (including placebo). An interim analysis is then carried out after the 50th
participant has been randomised, following which allocation probabilities for subsequent participants are
adapted to increase the potential for a successful trial outcome in light of the evidence collected so far. In
this example the adaptation was scheduled exactly half-way through the 100 planned randomisations but would
adaptations scheduled earlier or later in the recruitment phase perform better, or should they instead be spaced
evenly between randomisations throughout recruitment? We assessed the performance of ten adaptation
schedules [Table 1, section 1.2 (a)–(j)].
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4.1.3 Placebo allocation rate
The placebo allocation probability remained ﬁxed throughout the trial. For a design with J-1 active doses we had
initially planned to allocate participants to receive placebo with probability 1/J, such that participants during the
initial phase of recruitment, i.e. before the ﬁrst adaptation, would have equal probability of being allocated to any
of the J treatment arms. However, in order to cover the range of values successfully implemented in previous
multi-arm multi-stage adaptive trials6,7 we assessed the performance of designs using placebo allocation
probabilities of both 1/J and 2/J.
4.1.4 Criterion for adaptation of active dose randomisation probabilities
We evaluated two options for the choice of criterion for adaptation. One was the ‘play-the-winner’ rule where
subsequent trial participants are randomly allocated to one of the active doses in proportion to the posterior
probability that the treatment dose eﬀects at least some reduction in MBL as evaluated in the interim analysis.
Table 1. Design options and trial scenarios investigated in the design development study.
1. Design options
1.1 Active dose levels to include for investigation
(a) 0.4mg, 0.8mg, 1.0mg, 1.2mg, 1.5mg, 1.8mg
(b) 0.4mg, 1.0mg, 1.5mg, 1.8mg
1.2 Timing of adaptations (in terms of number of patients randomised)
(a) 33
(b) 50
(c) 66
(d) 10, 35 and 60
(e) 20, 45 and 70
(f) 49, 66 and 83
(g) 12, 24, 36, 48 and 60
(h) 16, 32, 50, 66 and 84
(i) 44, 55, 66, 77 and 88
(j) (no adaptation)
1.3 Placebo allocation rate (in design with J-1 active doses)
(a) 1/J
(b) 2/J
1.4 Criterion for adaptation (allocation probabilities are)
(a) scaled in proportion to probability that dose is efficacious (play-the-winner)
(b) based on predicted information gain resulting from a future randomisation at each dose
2. Scenarios
2.1 Variance of intra-participant MBL measurements
(a) se
2¼ (17.9mL)2
(b) se
2¼ (22.0mL)2
(c) se
2¼ (26.0mL)2 (only used when simulating heteroscedasticity)
2.2 Shape of dose-response curve
(a) Steep incline towards higher end of dose-range
(b) Slow incline with increasing dose levels
(c) Non-monotonic with maximum at 1.2mg
(d) Flat (i.e. no effect)
2.3 Magnitude of effect at maximum effective dose
(a) 8.2mL
(b) 16.4mL
2.4 Heteroscedasticity
(a) Absent
(b) Present
2.5 Mechanism of treatment
(a) Effect independent of baseline MBL
(b) Effect magnitude proportionate to baseline MBL
2.6 Enrolment rate
(a) 2 participants per month
(b) 4 participants per month
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The second adaptation criterion considered was a utility function which quantiﬁes the information gain from
future randomisations at each dose level. The function we used was the predicted variance of the response at the
current ED95 estimate after one future randomisation at each of the active doses. Subsequent trial participants
were then randomised in proportion to the predicted increase in precision that would result from a randomisation
at each dose.
To avoid computationally intensive nested MCMC routines, we used importance sampling8 as applied by Weir
et al.9 to predict the variance of the response at ED95 after one future randomisation. At each dose, the predicted
variance is based on M¼ 100 predictions for the future observed MBL diﬀerence and for each of these we estimate
the posterior predictive distribution for the response at ED95 based on t¼ 10,000 iterations of the MCMC
sampler.
4.1.5 Other considerations
The response variable, Y¼YfuYbl, was the diﬀerence between the baseline MBL measurements obtained at
screening, Ybl, and the follow-up MBL measurements, Yfu, collected during the treatment phases of the trial.
Early simulation results suggested that we were able to reduce the variance of the modelled outcome, Var(YjYbl)
by about 50% by collecting MBL measurements over two menstrual cycles at screening, Y1 and Y2, and similarly
over two cycles at follow-up, Y3 and Y4, and letting Ybl¼ (Y1þY2)/2 and Yfu¼ (Y3þY4)/2. As these twin
measurements at baseline and follow-up had been planned from the outset, and in light of the resultant reduction
in variance, we decided not to reduce the number of menstrual cycles monitored during a woman’s trial
participation.
4.2 Scenarios
The above design options were assessed under a number of alternative assumptions for the true dose-response
curve and other unknown parameters to ensure that the ﬁnal design chosen would perform well under a broad
range of scenarios. The choice of scenarios to be assessed was informed both by empirical data from previous
studies and through careful elicitation of expert opinion from the clinical team guided by the Sheﬃeld Elicitation
Framework (SHELF10).
The variance of repeated intra-participant MBL measurements, e
2, was likely to have a large eﬀect on the
probability of a successful trial. Data from an observational study11 suggested normally distributed within-
participant errors with a variance of e
2¼ 17.9mL. We also investigated scenarios with e2¼ 22.0mL and
e
2¼ 26.0mL. There was also some evidence from this source of increasing variance with greater MBL
measurements. Design options were therefore investigated under both homo- and heteroscedastic errors.
Heteroscedasticity was induced in the simulated within-participant errors through a simple parametric function
of the baseline MBL (Appendix 1) based on empirical data.11
The likely mechanism of a treatment eﬀect on participants’ MBL was also considered. Treatment eﬀects in
medical research are often modelled as an absolute change independent of baseline levels of the outcome variable.
In practice, the health improvement which results from a medical treatment is often dependent on the initial
severity of the problem. Generally, treatment of a bigger problem results in greater improvements in absolute
terms. Our investigation of candidate designs was therefore extended to include simulated scenarios where the
treatment eﬀect was 10% or 20% of the baseline MBL measurement at the most eﬀective dose, for small and large
simulated treatment eﬀect magnitudes respectively.
We did not incorporate the modelling of heteroscedasticity and interactions between treatment eﬀects and
baseline MBL levels in the NDLM, yet these were included as plausible scenarios essentially to assess the
robustness of the design for these scenarios where the model is misspeciﬁed.
We also included a number of scenarios for the shape of the true dose-response curve and the magnitude of the
treatment eﬀect at the maximum-eﬀective dose level (Figure 2). The trial enrolment rate was also believed to be of
importance since participants randomised during the follow-up phase of other participants and during the time
taken to carry out model re-estimation and adaptation, would not beneﬁt from adaptation. Typically, a fast
enrolment rate relative to the length of follow-up will reduce the beneﬁts of using an adaptive design.
Table 1 shows the range of design options and scenarios investigated in the design development study. Four
diﬀerent design options were included as outlined above (1. dose levels, 2. timing and number of adaptations, 3.
placebo allocation rate and 4. criterion for adaptation) and these were considered under various scenarios covering
assumptions in six critical areas (1. variance of MBL measurements, 2. shape and 3. magnitude of the dose-
response curve, 4. heteroscedastic error variance, 5. moderation of treatment eﬀect by baseline MBL and 6.
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enrolment rate). With reference to Table 1, one example of a simulated trial would have the design options (1.1.a),
(1.2.d), (1.3.c), (1.4.a) and scenario assumptions (2.1.b), (2.2.c), (2.3.b), (2.4.b), (2.5.b), (2.6.a), i.e. a trial with all
six active dose levels included, three adaptations (one after each of 10, 35 and 60 randomisations), a 2/7 placebo
allocation rate and a play-the-winner adaptation rule investigated under the scenario with MBL variance
parameter of (22mL)2, a non-monotonic dose-response curve with a treatment eﬀect of 16.4mL at the
maximum eﬀective dose, heteroscedastic error variance, treatment eﬀect proportionate to baseline MBL and a
trial enrolment rate of 2 participants per month.
5 Trial simulations
The performance of the many candidate designs was assessed under the various scenario options in a substantial
simulation exercise using a fractional factorial setup. We simulated all aspects of a trial including screening,
enrolment, randomisation, eﬀects of treatment, repeated interim analyses (at pre-deﬁned points during
enrolment as speciﬁed by the design), adaptation of subsequent randomisation probabilities, and at the end of
each trial, a ﬁnal analysis. Each such trial simulation was repeated 200 times to ensure good precision in the
performance characterisation of the design under the particular scenario. Independent data were generated for
each simulated trial and design-scenario combination. Using a single control program we conducted the entire
simulation exercise from within SAS software version 9.3 (SAS Institute Inc., Cary, NC, United States) which in
turn invoked WinBUGS5 for Bayesian model estimation and empirical estimates of posterior distributions. (The
paper by Zhang et al. (2008)12 is an excellent resource on how to control WinBUGS via a SAS program.)
At the core of the exercise was the simulation engine which generated the simulated trial data. We aimed to
mimic a real-life trial as closely as possible by simulating screening data at the eligibility stage before enrolment.
The DexFEM trial recruits participants who suﬀer from heavy menstrual bleeding. For the purpose of the trial this
has been deﬁned through the inclusion criteria as average menstrual blood loss per period (collected over two
menstrual cycles at screening and objectively measured in a laboratory) in excess of 50mL.
The distribution of menstrual blood loss in the general population of women of reproductive age is heavily
skewed with most women’s MBL measuring below 50mL per period while some experience very high levels of
MBL. Informed by data from previous studies on MBL levels in the general population13,14 and a more selected
Figure 2. Four scenarios for the true dose-response relationship.
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clinical study population,15 we approximated this distribution using a log-normal distribution and modelled MBL
levels in our simulation study on this. To be included in our simulated trials, potential participants had to have an
average MBL of at least 50mL over the two screening measurements. Measurements taken from the same subject
were correlated and were modelled in a two-stage procedure:
MBL measurements from subject i at time point t were modelled as the sum of two random variables
Yit ¼ Si þ Eit
Si represented the underlying mean MBL level for subject i and was generated from the log-normal distribution
referred to above. The second term, Eit,N(0, e2) denoted the random deviation in the observed MBL at time t
from the subject’s underlying mean. We had evidence11 to support the assumption that E was approximately
normally distributed with e¼ 17.9mL. S and E were assumed independent at ﬁrst. For each subject, we
therefore simulated just one value for S but a separate value for E for every new observation thereby inducing
compound symmetry in the covariance structure across repeated measurements. This approach had the added
advantage that regression to themean was naturally imposed on the simulated data as part of the enrolment process.
After collecting two simulated measurements at screening, Y1 and Y2, eligible participants (i.e. those with
(Y1þY2)/2 50mL) were enrolled in the trial and allocated at random to receive either Placebo with
probability p or one of J 1 active doses with equal probability (1p)/(J 1).
Next, we added a treatment eﬀect, Dj(i), to participants’ underlying mean MBL level according to the speciﬁed
dose-response curve under the particular scenario. Having added a treatment eﬀect we then simulated two further
MBL measurements at follow up as Yit¼SiþDj(i)þEit, for t¼ {3,4}.
The process of screening and randomising eligible participants, adding treatment eﬀects and sampling MBL
outcomes at follow-up was then repeated until the ﬁrst interim analysis (when a certain number of participants had
been randomised in accordance with the adaptation schedule). At this point we used a SAS macro16 to manipulate
variables containing participants’ randomised dose levels and MBL data from screening and follow-up into a
format appropriate for parsing in WinBUGS. The interim analysis was then executed with the relevant data ﬁles
and model script through a batch call in SAS.
An estimate of the dose-response curve was then computed in WinBUGS by ﬁtting the NDLM (section 3) to the
simulated interim data. Estimates of the treatment eﬀects at each dose level were derived as the contrast
 j¼ j 1, for j¼ {2, . . . , J}.
Model parameter estimates were based on 10,000 simulated draws from the marginal posterior distributions
having discarded the ﬁrst 5000 iterations from the sampler (the burn-in). Convergence of the MCMC sampler was
monitored for selected design-scenario combinations by sampling from two chains simultaneously using over-
dispersed initial values and calculating the BGR diagnostic,17 coupled with visual inspection of the iteration
histories.
Posterior estimates of the treatment eﬀects, and if appropriate, other relevant quantities necessary for
evaluating the utility function were then saved to text ﬁles and imported into SAS for processing. Finally,
allocation probabilities were updated according to the pre-speciﬁed adaptation rules and applied to
randomisations of new participants enrolling into the next stage of the trial. The process was repeated until the
next interim analysis, and so on, until all 100 participants were randomised. At the end of the trial the ﬁnal model
estimates were derived. A successful trial was deﬁned as one where the posterior probability that  j> 0 was in
excess of 97.5% for at least one of the active doses, j2 {2, . . . , J}. The trial outcome (success or failure) was
recorded along with other parameters used for monitoring the simulations. These included the intermediate and
ﬁnal model parameter estimates, the number of participants randomised to each dose level overall and at each
phase of the trial, and the utility function evaluated at each dose level and phase of the trial. The process was
repeated 200 times for each trial design under the assumed scenario. The magnitude of the mean treatment eﬀect
estimates at each dose level was monitored to check for bias.
A fully factorial design would have entailed investigating nearly 10,000 unique design-scenario combinations
requiring almost 2,000,000 trial simulations. With each trial simulation taking up to 3.5min to complete on a
standard speciﬁcation desktop PC, this number of simulations was not feasible. Instead, we assessed a selected 142
relevant combinations of trial designs and scenarios amounting to 1.5% of a fully factorial design. The tasks and
dialogue between the SAS Software and WinBUGS are summarised in Figure 3. A detailed description of the
simulation study including plans for the design options and scenarios to be assessed was reviewed by the
independent data monitoring committee before the simulation was executed.
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6 Methods for the analysis of simulation results
The changing pattern of randomised treatment allocations over the course of simulated trials was summarised
graphically to illustrate the extent to which the utility function being applied at each adaptation achieved the
desired modiﬁcations to the randomisation probabilities.
Specify & save 
WinBUGS model ﬁle  
Specify & save inial 
values ﬁle  
Specify & save script 
ﬁle with WinBUGS 
commands
Specify & save batch 
ﬁle with commands 
to execute 
WinBUGS using 
relevant script, 
model and data ﬁles 
Simulate trial data & 
save to disk
Execute batch ﬁle
WinBUGS script ﬁle is 
executed
NDLM is ﬁed to 
simulated data
Posterior esmates 
are derived of 
treatment eﬀects at 
each dose level and 
other quanes 
necessary for 
evaluaon of the 
ulity funcon
Esmates are saved 
in log and CODA ﬁles
Import WinBUGS data 
ﬁles
Evaluate ulity 
funcon as 
appropriate 
Adapt randomisaon 
probabilies
End-of-trial 
evaluaon
Specify design- 
scenario combinaon 
to invesgate 
Repeat trial 200 m
es
Repeat for each phase of the trial
Repeat for each design / scenario com
binaon in the fraconal factorial desi gn
Figure 3. The Simulation engine. White (grey) boxes indicate tasks performed in SAS (WinBUGS).
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The quantitative design properties of interest were:
(1) Family-wise type I error rate Under the trial scenario where no Dexamethasone dose has any beneﬁt over
placebo (a ‘‘ﬂat’’ dose-response curve), the probability that the trial wrongly concludes that at least one
Dexamethasone dose is eﬃcacious.
(2) Trial powerHere we use the statistical deﬁnition of disjunctive power:18 the probability that, in the presence of a
genuineDexamethasone eﬀect, the trial correctly identiﬁes at least oneDexamethasone dose as being eﬃcacious.
We used a normal linear model to analyse the results from the fractional factorial simulation study. We modelled
the overall eﬀect of each design option across a range of trial scenarios. Separate models were ﬁtted for trial power
(for simulated dose-response curves that included a true beneﬁt of Dexamethasone) and type I error rate (for
scenarios in which a ‘‘ﬂat’’ dose-response curve was simulated). Important two-way interactions between design
options and trial scenarios were investigated within the normal linear model, for example to explore whether the
impact on trial power of increasing the number of adaptations diﬀered across a range of dose-response curve shapes.
For each design option and trial scenario the mean change in statistical power relative to the reference design
option or trial scenario was estimated from the normal linear model alongside its corresponding 95% conﬁdence
interval.
7 Results from the simulation study
Figure 4 illustrates the evolving pattern of randomisations for one of the types of adaptation evaluated: three in-
trial adaptations after 20, 45 and 70 patients randomised. The randomisation probabilities were adapted during
the course of the trial using the ‘play-the-winner’ criterion described in section 4.
Figure 5 conﬁrms that none of the design options simulated was associated with a signiﬁcant change in the type
I error rate estimated from the simulations. The overall type I error rate of 6.2% (95% CI, 5.5% to 6.9%) was
acceptable.
Figure 6 illustrates the association between three design options and statistical power. Adaptation according to the
precision of the estimated response at the ED95 (the minimum dose with near-maximal eﬃcacy) showed a slight
advantage over adaptation of allocation probabilities in proportion to the current estimate of the probability that a
dose is eﬃcacious inMBL reduction. Statistical powerwas greater if only four rather than six active doses were studied,
although the six dose designs performed with acceptable power across scenarios. Having a higher proportion of
participants randomised to placebo throughout the trial (2/7 versus 1/7) led to a substantial gain in power.
Figure 7 describes the performance of various adaptation schedules in terms of statistical power. Increasing the
number of adaptations was beneﬁcial; with ﬁve adaptations, spreading those evenly throughout recruitment after
16, 32, 50, 66 and 84 randomisations gave the highest point estimate of statistical power.
Table 2 reports the relative impact of various design options and trial scenarios on statistical power by listing
the main eﬀects from the normal linear modelling. Recruitment rate and presence of heteroscedasticity were not
signiﬁcantly associated with trial power, although some variation in power was observed for diﬀerent shapes of
the dose-response curve. As expected, the magnitude of treatment eﬀect and variability in the primary outcome
were the dominant inﬂuences on power. Increasing the proportion randomised to placebo, reducing the number
of Dexamethasone doses studied and various schedules of adaptive randomisation also provided a beneﬁt in
terms of statistical power. No important two-way interactions were identiﬁed in the normal linear modelling.
8 Rationale for the adaptive design selected for DexFEM
We chose the following adaptive design for the DexFEM randomised, double-blind, placebo controlled trial to
identify the minimum Dexamethasone dose with near-maximal eﬃcacy.
(a) ﬁve adaptations;
(b) adaptations spaced evenly across the randomisation period, adapting after 16, 32, 50, 66, 84 patients have
been randomised;
(c) use of a utility function to guide the adaptations based on the precision (the reciprocal of the variance) of the
estimated response at the ED95 (the minimum dose with near-maximal eﬃcacy) after one further patient has
been randomised;
(d) 6 dexamethasone doses (0.4, 0.8, 1.0, 1.2, 1.5, 1.8mg total daily dose);
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(e) 28.6% (2/7) of patients allocated to placebo throughout.
The simulation ﬁndings and other key considerations informed the design choice. Successive increases in the
number of adaptations led to corresponding increases in statistical power. While there was no marked advantage
of ﬁve adaptations over three, a 5-adaptation design with adaptations evenly spaced throughout recruitment was
considered feasible. As well as giving fractionally the highest statistical power in simulations, the design is
straightforward to communicate to collaborators. We selected the utility function providing slightly greater
statistical power. The improved power of a 4-dose design over a 6-dose design is somewhat counter-intuitive.
This may be because in our simulated example, the subset of four doses by chance included points on the dose
response curve with greatest eﬃcacy. We nevertheless selected the 6-dose design, because we aimed to study the
largest possible number of doses while retaining acceptable statistical power. Finally, we opted to randomise 2/7 of
patients to placebo as this provided much greater power than the alternative.
The statistical power of such a design estimated from the normal linear model is 93.8% (95% conﬁdence
interval 91.9% to 95.8%) for simulations on all shapes of dose response curve with a mean beneﬁt over
placebo of 16.4mL and a within patient MBL standard deviation of 17.9mL, averaged across
heteroscedasticity (present/absent) and interaction with baseline MBL (present/absent), for a trial randomising
four patients per month. For comparison, a conventional non-adaptive design studying all six doses under similar
scenarios would have 82.5% power.
9 Discussion
9.1 Summary of results
We identiﬁed a Bayesian adaptive dose-ﬁnding design which had high statistical power compared with a standard
parallel group design and which performed consistently regardless of trial recruitment rate, shape of dose-response
Figure 4. Proportion of patients randomised to each of seven trial arms during the four phases of an adaptive trial with three
adaptations and fixed 28.6% allocation probability on placebo. Phase 1: before adaptation commences, equal allocation probability
across all active doses. Phase 2: after adaptation #1 based on MBL outcome data collected on the first 20 patients. Phase 3: after
adaptation #2 based on MBL outcome data collected on the first 45 patients. Phase 4: after adaptation #3 based on MBL outcome data
collected on the first 70 patients. The data presented are the average proportions observed from 200 simulated trial runs. The most
effective dose was between 1.0 and 1.2mg.
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curve and deviations from the model assumptions. A notable ﬁnding was the substantial gain in power from
allocating a greater proportion of participants to placebo: this is consistent with what would be expected from
optimal design theory and with what has been found in other parallel group designs evaluating multiple
treatments.19,6
Our simulation studies conﬁrmed that the use of an adaptive design conferred eﬃciency gains over a
conventional parallel group design. The statistical power of our chosen adaptive design is substantially greater
than that of a design which did not incorporate adaptations (93.6% versus 82.5%). This increase in eﬃciency is
consistent with that found in the context of adaptive seamless phase 2/3 designs20 where a similar level of
improvement in statistical power equated to a 25–40% saving in sample size.
The modelling of dose-response using the NDLM, coupled with the eﬃciency gains of our adaptive design
enables a greater number of doses to be studied; otherwise one is required to select a subset of all available doses
without prior knowledge of the dose response.21 This necessary pre-selection of doses may lead to further loss of
statistical power if, by chance, the subset of doses selected does not include any of the more eﬃcacious doses.
9.2 Influences on design choice
The elicitation of expert clinician opinion described in section 4 indicated that from a mechanistic perspective a
monotone increasing dose response curve for Dexamethasone could not be guaranteed. This required us to
consider more sophisticated modelling of dose response, rather than simply evaluating the highest feasible dose
in a two-arm comparison versus placebo.
Figure 5. (a) Estimated type I error rate and 95% CI under various scenarios. (b) Estimated type I error rate and 95% CI under
various design options. Adaptation rule #1: adapts percentage randomised to each dose in proportion to the current estimate of the
probability that it is efficacious in MBL reduction. Adaptation rule #2: alters randomisation according to the precision of the estimated
response at the ED95 (the minimum dose with near-maximal efficacy). (c) Estimated type I error rate and 95% CI, overall and under
various design options.
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The upper limit of six on the number of doses being evaluated was dictated by practical considerations: it
enables the doses under study to be reasonably closely spaced, while simplifying the drug packaging process and
minimising wastage of drug for doses whose allocation probabilities are down-weighted following an adaptation.
Our simulations evaluated only two of the possible utility functions. We selected these on the basis of ease of
interpretation (the ‘‘play the winner’’ approach) and eﬃciency of adaptation demonstrated in previous studies
(quantifying the gain in information about the response at the current estimate of the ED95).21,22
Although the fractional factorial simulation study design led to confounding of main eﬀects with higher-order
interaction terms, this was not a substantial constraint as we were still able to explore two-way interactions
between design options.
Given the volumetric nature of the MBL outcome, we might have expected there to be some deviations from the
normality assumptions in the NDLM. However, these did not prove problematic, perhaps in part because our
model studied the change from baseline and also adjusted for the baseline measurement. Had we identiﬁed
evidence of non-normal errors, an alternative option would have been to model the log-transformed MBL instead.
9.3 Practical aspects
Although the importance sampling approach assisted with the computational eﬃciency of the simulations,
nevertheless a period of 10 months was required to develop and conduct the simulation study. Much of this
time involved preparing the suite of statistical programs and collaborating with experts in the therapeutic area to
ensure that a credible set of design options and assumptions were considered in the simulation study; the actual
simulations required approximately two months of processing time on a desktop PC. In part this was because a
‘‘belt and braces’’ approach to the importance sampling was taken, with m¼ 100 observations being simulated for
each dose at each adaptation and 10,000 MCMC runs being performed on each. This is consistent with other
work9 which suggested that at the stage when only a low number of patients have been randomised to a trial, larger
numbers of simulated observations and MCMC runs are preferable. In a larger trial than DexFEM, or in the later
stages of DexFEM itself, a smaller value of m and fewer MCMC runs should also be adequate.9
Figure 5. Continued.
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We implemented our simulations and adaptive design without the development of bespoke software packages,
as use of SAS and WinBUGS would maximise the generalisability of our ﬁndings and the reuse of our
programming code in other applications. The overall scope of our simulations (200 trials per scenario; 150
scenarios; 10,000 MCMC runs following a 5000 iteration burn-in for each model estimation step) was therefore
inﬂuenced by this use of generic rather than tailor-made software which will have had an impact on computational
eﬃciency and simulation run times. In addition to making use of readily available software, we linked programs in
SAS and WinBUGS to form a single integrated package through which to deliver the entire design development
study.
9.4 Technical considerations
The nature of the adaptive design means that not all of the placebo comparator patients are being studied
contemporaneously with those randomised to a Dexamethasone dose. This is particularly notable for the doses
given increased randomisation probabilities in the later stages of the adaptive design. In order to account for this,
the ﬁnal analysis of the trial should be stratiﬁed by adaptation stage to ensure that within each stage a
contemporaneous randomised comparison is being considered.23 This accounts for so-called ‘‘cohort eﬀects’’
that would be induced by trends in participant characteristics or protocol changes during the trial and ensures
that the study retains the perspective of concurrent control.24 This consideration applies to a broad range of
adaptive designs, including adaptive seamless designs, and is not restricted to the speciﬁc design implemented in
DexFEM.
The optimal spacing of adaptations will depend on the rate at which participants are randomised to the trial25
as well as the length of follow up time between randomisation and assessment of outcome. Our result showing that
ﬁve adaptations equally spaced throughout recruitment had marginally the greatest statistical power is consistent
with the ﬁndings in adaptive seamless phase II/III designs20 which gave greatest adaptive seamless design eﬃciency
when equal numbers of patients were included in phase II and phase III, rather than in the ratio 1:2 or 1:3. As our
Figure 5. Continued.
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MBL primary outcome measure is available soon after treatment relative to the length of the period of recruitment
to the trial, there was no requirement to seek an intermediate outcome on which to base adaptations, as
recommended in situations where the primary outcome is measured following a lengthy follow-up period.26 An
optimal group sequential testing framework is available in such a scenario.27
Our proposed design adapts on eﬃcacy only, which is justiﬁable as Dexamethasone is already licenced and its
safety proﬁle well-established for much higher acute doses than the repeated doses for longer-term use that mimic
physiological glucocorticoid secretion which are studied in DexFEM. In other situations, there would be the scope
to adapt simultaneously on both eﬃcacy and toxicity data, for example using the ‘‘trinary’’ ordinal outcome
approach28 which combines these outcomes as 0: no eﬃcacy and no toxicity, 1: eﬃcacy and no toxicity and 2:
toxicity. Thall and Cook 29 develop these approaches further by considering a bivariate binary outcome which
incorporates both eﬃcacy and safety information.
10 Conclusion
This simulation study has enabled us to develop a Bayesian response-adaptive design which maximises what can be
learned about the Dexamethasone dose-response relationship from this clinical trial in heavy menstrual bleeding,
substantially gaining eﬃciency over a standard parallel group design. The ﬂexible approach we have reported
identiﬁes a design which performs robustly across a range of potential trial scenarios, and which remains feasible
to deliver as it incorporates a manageable number of adaptations and is based on widely available statistical
software. In a separate paper we will report on the technical aspects of using simulations to inform the
Figure 6. Main effects on statistical power of three design options. Estimates are averaged over all scenarios with a ‘genuine’
treatment effect. Adaptation rule #1: allocate in proportion to current probability that the treatment dose affects at least some
reduction in MBL. Adaptation rule #2: based on the precision (the reciprocal of the variance) of the estimated response at the ED95
(the minimum dose with near-maximal efficacy) after one further patient has been randomised (one-step-ahead approach). The vertical
bars indicate 95% confidence intervals.
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Figure 7. Main effect of the adaptation schedule. Estimates are averaged over all scenarios with a ‘genuine’ treatment effect. The
labels along the horizontal axis indicate the number and timing of adaptations (e.g. ‘10;35;60’ is a design with adaptations after 10, 35
and 60 randomisations). The vertical bars indicate 95% confidence intervals. The reference category is ‘no adaptation’.
Table 2. Summary of main effects of design features from normal linear modelling of simulation outputs for all scenarios containing a
genuine dexamethasone effect.
Levels
Mean power change
versus reference P-valuea
Scenario Curve (1) Sine curve: steep 9% <0.0001
(2) Sine curve: slow 5% <0.0001
(3) Non-monotone Reference –
Variance (17.9mL)2 þ17% <0.0001
(22mL)2 þ8% <0.0001
(26mL)2 Reference –
Randomisation rate 2 pt/month -0.7% 0.24
4 pt/month Reference –
Maximum mean effect of
dexamethasone
16.4mL þ44% <0.0001
8.2mL Reference –
Mechanism No interaction þ3% 0.007
Treatment-BL interaction Reference –
Heteroscedasticity Absent þ0.4% 0.76
Present Reference –
Design option Timing of adaptations
(in terms of number of
patients randomised)
33 0% 0.86
50 þ4% 0.0010
66 þ6% 0.0058
10; 35; 60 þ6% 0.013
(continued)
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development of an adaptive design, providing tips on how best to implement this using SAS and WinBUGS and
including all of our statistical programming code.
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Appendix 1
There is evidence in Fraser et al.11 that MBL scores are subject to heteroscedastic error variance: women who
experience greater average MBL tend to exhibit more variability in their observed MBL measurements. It was
important to investigate the eﬀects of such a mechanism and we therefore included scenarios in our work-up study
which simulated separate error variances as a function of Si, the underlying mean MBL for participant i. Thus,
individual error variances were generated as
Var Eið Þ ¼ Aþ B exp Si=100ð Þ  Cð Þ
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where Ei is the random deviation in the observed MBL from Si, C is a mean centring constant and A is the variance
under scenarios with homoscedastic error variance (i.e. when B¼ 0). For scenarios allowing diﬀerent error
variances for each participant we used a value (198) for B which was estimated in a separate model of
empirical data from the Fraser study.11 Heteroscedastic error variances were simulated for each of the relevant
three values of A: (17.9)2, (22.0)2 and (26.0)2. (For completeness, the mean centring constant used was C¼ 2.837.)
For near-zero values of S this function for Var(E) yielded unrealistically small or even negative values. The
function was therefore restricted to not produce values below Var(E)¼ 6. This is consistent with the variance
observed amongst the patients in the Fraser study11 with the lowest observed mean MBL. At the other end of the
scale, for values of S near 400mL the variance function yielded extremely large values. Consequently the function
was also restricted to not produce values above Var(E)¼ (70.7)2¼ 5000, which was about twice the largest
observed variance in the Fraser study11.
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